CSPC Pharmaceutical’s New Antifungal Drug Approved
Company Announcements

CSPC Pharmaceutical’s New Antifungal Drug Approved

CSPC Pharmaceutical Group (HK:1093) has released an update.

CSPC Pharmaceutical Group Limited has made a notable advancement in the pharmaceutical market with their latest product, Amphotericin B Liposome for Injection, receiving drug registration approval in China. This product, designed to treat systemic fungal infections, febrile neutropenia in suspected fungal infections, and visceral leishmaniasis, also reduces nephrotoxicity and improves therapeutic outcomes due to its innovative liposomal delivery system.

For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskCSPC Pharmaceutical Group to Announce Financial Results
TipRanks HongKong Auto-Generated NewsdeskCSPC Pharmaceutical Warns of Profit Decline Amid Drug Sales Challenges
TipRanks HongKong Auto-Generated NewsdeskCSPC Pharma Advances CAR-T Therapy for Myasthenia Gravis
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App